EMEA and FDA boost scope of transatlantic co-operation
The European Medicines Agency (EMEA) and the US Food & Drug Administration (FDA) have agreed to expand their co-operation to the regulation of advanced-therapy medicines and nanotechnology-derived medicinal products.
The European Medicines Agency (EMEA) and the US Food & Drug Administration (FDA) have agreed to expand their co-operation to the regulation of advanced-therapy medicines and nanotechnology-derived medicinal products.
Building on the co-operation they have forged in the areas of oncology, vaccines, orphan medicines, paediatric medicines, and more recently pharmacovigilance information, the two agencies agreed to co-operate in these new areas at a meeting in London at the beginning of October.
A joint communique declared: "Transatlantic co-operation activities continue to be successful in protecting and promoting global human and animal health, reducing the regulatory burden and costs so that innovative medicines can be brought to patients in a timely manner."